SynthesisThe Journal of antimicrobial chemotherapy2022
Invasive Trichoderma spp. infections: clinical presentation and outcome of cases from the literature and the FungiScope® registry.
Synthesis in The Journal of antimicrobial chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Rezafungin for Salvage or Consolidation Therapy of Invasive Fungal Disease: Experience in Real-World Clinical Practice.Mycoses · 2026Article
- Trichoderma harzianum fungemia following COVID-19-related immune dysregulation in an immunocompetent patient: a case diagnosed by mNGS.BMC infectious diseases · 2026Article
- Molecular Characterisation of Fungi Populations in the Chronic Wounds of Filarial Lymphedema Patients in Southern Ghana: A Cross-Sectional Study.Health science reports · 2025Article
- Periprosthetic Joint Infection Caused by Trichoderma: Is It Plausible?Diagnostics (Basel, Switzerland) · 2025Article
- Invasive Trichoderma longibrachiatum breakthrough infection in a hematology patient.Medical mycology case reports · 2025Article
- Evaluation of two MALDI-TOF MS systems and extraction methods for identification of filamentous fungi recovered from clinical specimens.Journal of clinical microbiology · 2025Article
- InvasiveMedical mycology case reports · 2024Article
- Synthetic and Natural Antifungal Substances in Cereal Grain Protection: A Review of Bright and Dark Sides.Molecules (Basel, Switzerland) · 2024Review
- Cutaneous Hyalohyphomycosis and Its Atypical Clinical Presentations in Immunosuppressed Patients.Life (Basel, Switzerland) · 2024Review
- Microbial Pathogens in Aquaponics Potentially Hazardous for Human Health.Microorganisms · 2023Review
- Review
- Non-Journal of fungi (Basel, Switzerland) · 2023Review
- Necrotizing gingival infection due toTherapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 8 countries.
Funding
Abstract
backgroundTrichoderma spp. are filamentous fungi causing invasive fungal diseases in patients with haematological malignancies and in peritoneal dialysis patients.
objectivesTo analyse clinical presentation, predisposing factors, treatment and outcome of Trichoderma infections.
methodsA systematic literature review was conducted for published cases of invasive Trichoderma infection in PubMed until December 2021 and by reviewing the included studies' references. Cases from the FungiScope® registry were added to a combined analysis.
resultsWe identified 50 invasive infections due to Trichoderma species, including 11 in the FungiScope® registry. The main underlying conditions were haematological malignancies in 19 and continuous ambulatory peritoneal dialysis (CAPD) in 10 cases. The most prevalent infection sites were lung (42%) and peritoneum (22%). Systemic antifungal therapy was administered in 42 cases (84%), mostly amphotericin B (n = 27, lipid-based formulation 13/27) and voriconazole in 15 cases (30%). Surgical interventions were performed in 13 cases (26%). Overall mortality was 48% (n = 24) and highest for allogeneic HSCT and solid organ transplantation (SOT) recipients [80% (4/5) and 77% (7/9), respectively]. In patients treated with amphotericin B, voriconazole and caspofungin, mortality was 55% (15/27), 46% (7/15) and 28% (2/7), respectively. Three out of four patients treated with a combination therapy of voriconazole and caspofungin survived.
conclusionsDespite treatment with antifungal therapies and surgery, invasive Trichoderma infections are life-threatening complications in immunocompromised patients, especially after HSCT and SOT. In addition, Trichoderma spp. mainly affect the lungs in patients with haematological malignancies and the peritoneum in CAPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.